News - MedTech & Diagnostics
Reduced TGA charges for medical devices listed on the prostheses list

MedTech News: In response to the suspension of elective surgery due to COVID-19 and the significant impact this has had on parts of the medical devices industry, the Government has agreed to provide a 50% reduction in annual charges for certain medical devices.
The 50% reduction in annual charges will be prescribed for the 2020-21 financial year for medical devices included in the Australian Register of Therapeutic Goods (ARTG) as Class IIa, IIb, III and AIMD and which are listed prostheses as defined in the Private Health Insurance (Prostheses) Rules (No.1) 2020, as in force on 8 April 2020.

These charges are in the Therapeutic Goods (Charges) Regulations 2018
No action is required by eligible sponsors as the Therapeutic Goods Administration (TGA) will use the published Prostheses List (PL) as in force on 8 April 2020 with reference to the ARTG inclusion number to identify those devices which will be subject to the reduced charges. If the ARTG inclusion number for a device on the PL as in force on 8 April 2020 is not correct, contact the TGA by 31 July 2020.
The reduced annual charge would also apply to an ARTG entry where multiple products are included in the entry and only some products covered by the entry are listed on the PL.
Sponsors will receive an invoice in August for the 2020-21 annual charges, which will automatically include the reduced charges for such devices.
The complete TGA fees and charges schedule is available on the TGA website.
Digital & Innovation
Health sector faces new privacy obligations
Healthcare organisations must update their privacy policies by 10 December if they use artificial intelligence (AI) or a computer program […]
MoreNews - Pharmaceuticals
TGA approves new antibiotic but AMR blind spot remains a critical concern
The Therapeutic Goods Administration (TGA) has approved a new antibiotic for the treatment of carbapenem-resistant Gram-negative bacterial infections. Developed by […]
MoreNews - MedTech & Diagnostics
BCAL Diagnostics rejects merger speculation
ASX-listed BCAL Diagnostics has moved to quash speculation of a potential three-way merger involving Genetic Signatures and Microba Life Sciences, […]
MoreNews - Pharmaceuticals
Australia backs infectious disease innovation as US funding faces more cuts
Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD […]
More